Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 12...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 43; číslo 33; s. 3573
Hlavní autoři:	Neelapu, Sattva S, Chavez, Julio C, Sehgal, Alison R, Epperla, Narendranath, Ulrickson, Matthew L, Bachy, Emmanuel, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Oluwole, Olalekan O, Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph D, Wulff, Jacob, Shen, Rhine R, Zhang, Wangshu, Poddar, Soumya, Miao, Harry, Nikolajeva, Olga, Jacobson, Caron A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 20.11.2025
Témata:	Adult Aged Aged, 80 and over Antigens, CD19 - immunology Biological Products Female Follow-Up Studies Humans Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Lymphoma, Follicular - immunology Lymphoma, Follicular - mortality Lymphoma, Follicular - therapy Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - therapy Male Middle Aged Neoplasm Recurrence, Local - therapy Progression-Free Survival Receptors, Chimeric Antigen
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 127 with FL and 31 with marginal zone lymphoma) after a median follow-up of 64.6 months. Patients underwent leukapheresis and received lymphodepleting chemotherapy and axi-cel (2 × 10 CAR T cells/kg). The overall response rate was 90% (75% complete response rate). The median duration of response was 60.4 months, and the median progression-free survival (PFS) was 62.2 months; median time to next treatment and overall survival were not reached (NR). At data cutoff, 55% of patients were alive without requiring subsequent anticancer therapy. Median lymphoma-specific PFS in patients with FL was NR; 34% had progression or death due to lymphoma or study treatment. Notably, after 30 months postinfusion, progression or lymphoma-related deaths were rare. Late-onset toxicities were infrequent and largely unrelated to axi-cel. Durable response and prolonged survival in FL were associated with robust early CAR T-cell expansion and naïve product phenotype. These findings confirm sustained responses and manageable safety with axi-cel in the long term among patients with R/R iNHL and its potential as a curative therapy in FL.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1527-7755 1527-7755
DOI:	10.1200/JCO-25-00668